Replimune surges after FDA advisers back skin cancer drug
- Posted on July 31, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Replimune surges after FDA advisers back skin cancer drug
By Christy Santhosh July 31 (Reuters) - Shares of Replimune more than doubled premarket on Friday after the U.S. Food and Drug Administration's panel of outside advisers voted to back trial results for its drug for a type of skin cancer. Late on Thursday, the panel voted 10 to 3 in favor of the drug, RP1, concluding that trial data showed patient benefit, despite concerns raised earlier in the
